| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $-0.49 | - | - |
| Q4'25 | $-1.16 | $-0.69 | +40.8% |
| Q3'25 | $-0.40 | $-0.47 | -20.3% |
| Q2'25 | $-0.41 | $2.45 | +697.1% |
| Q1'25 | $-0.45 | $-0.39 | +12.7% |
| Q4'24 | $-0.39 | $-0.37 | +4.8% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $601M | - | - |
| Q4'25 | $251M | $228M | -9.3% |
| Q3'25 | - | $146M | - |
| Q2'25 | - | $105M | - |
| Q1'25 | - | $55M | - |
| Q4'24 | - | $38M | - |
Market Data
NBIS is currently trading at $222.48, giving Nebius Group N.V. a market cap of 50.71B and a P/E ratio of 62.0. Today's range spans $210.40–$233.60, with shares opening at $227.86 and moving down $3.86 (1.7%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 85/100.
Over the past year NBIS has traded between $34.72 and $233.73 - the current price is +540.8% off the 52-week low and -4.8% from the high. 24 analysts cover the stock with a Buy consensus and a mean 12-month target of $230.77 (range $120.00–$291.00), implying upside of +3.7%.
The earnings revision cycle for Nebius Group N.V. (NBIS) may be in an upward phase - large-cap Communication Services names (50.71B market cap) showing bullish technicals (100/100, BUY) alongside bullish sentiment (85/100) often see analyst target increases in the weeks following this kind of dual-signal alignment. Price: $222.48 (near 52-week highs). (P/E: 62.0) Range: $34.72–$233.73. The chart frequently leads the fundamental revision, and the chart is bullish.
What makes NBIS's BUY setup (100/100) particularly actionable at 50.71B in Communication Services capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $222.48 (near 52-week highs in $34.72–$233.73), with sentiment running bullish at 85/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).